Guideline-directed medical therapy for HFrEF was prescribed to only 20% of primary care patients, with no significant increase in prescription rates following the ESC 2021 guidelines.
Cross-Sectional (n=558)
Yes
In a Swedish primary care cohort, HFpEF was the most common heart failure subtype, and adherence to quadruple guideline-directed medical therapy for HFrEF remained low (20%) with no improvement following the 2021 ESC guidelines.
OBJECTIVES: We aimed to describe clinical and diagnostic characteristics of primary care patients with heart failure and physicians' adherence to guideline-directed medical therapy (GDMT) for treating chronic heart failure. DESIGN: Cross-sectional study based on baseline data from the prospective primary care-based study Heart failure in Southern Sweden (HISS). SETTING: Patients with heart failure were included from 20 primary healthcare centres in the southernmost region of Sweden (Skåne). PARTICIPANTS: Between 2020 and 2023, patients were included in HISS, resulting in a total of 587 participants. Of these, 558 patients (95% of the HISS participants) had available data on left ventricular ejection fraction and were included in this study. Adult patients aged 18 years or older diagnosed with heart failure (International Classification of Diseases, 10th Revision codes I50, I11.0, I42, I43) were considered eligible for inclusion in HISS. Community-dwelling patients with assisted care were excluded. PRIMARY AND SECONDARY OUTCOMES: The primary outcome measures were distribution of heart failure subtypes and prescribed medications. The secondary outcomes were temporal trends in GDMT and the association between physicians' adherence to GDMT and clinical characteristics of patients, using logistic regression models. RESULTS: Heart failure with preserved ejection fraction (HFpEF) was the most prevalent subtype (42%), followed by mildly reduced (30%) and reduced ejection fraction (HFrEF, 28%). Among patients with HFrEF, 20% were prescribed the recommended GDMT according to the European Society of Cardiology (ESC) 2021 guidelines, which consisted of a renin-angiotensin system inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist and a sodium-glucose 2 inhibitor. We observed no significant change in the prescribing trends for the quadruple therapy in patients with HFrEF when comparing the 2 years before and after the publication of the ESC 2021 guidelines. Similarly, we observed no association between patient characteristics and the prescription of GDMT according to ESC 2021 for patients with HFrEF. CONCLUSION: HFpEF was the most prevalent subtype, with conclusive and recent echocardiography data among two-thirds of the cohort. Temporal trends in prescription patterns showed no appreciable increase in the use of GDMT for HFrEF during the two years following guideline publication compared with the two preceding years. These findings indicate a need for inclusion of primary care patients as a basis for intensified medical recommendations and implementation strategies. TRIAL REGISTRATION NUMBER: NCT04129658.
Söderberg et al. (Sat,) conducted a cross-sectional in Heart failure (n=558). Guideline-directed medical therapy (GDMT) was evaluated on Distribution of heart failure subtypes and prescribed medications. Guideline-directed medical therapy for HFrEF was prescribed to only 20% of primary care patients, with no significant increase in prescription rates following the ESC 2021 guidelines.